Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 4450
Single User License Price INR 315817
Corporate User License Price USD 6250
Corporate User License Price INR 443563
Request a Quote

Report Title

Global Avascular Necrosis Market Research Report - Forecast to 2024

Quote Request for License Type
License Type Price  
Single User License USD 4450
Enterprise Wide License USD 6250
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Global Avascular Necrosis Market Research Report - Forecast to 2024


Quote Request for License Type
License Type Price  
Single User License USD 4450
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Global Avascular Necrosis Market Research Report - Forecast to 2024

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Global Avascular Necrosis Market Research Report - Forecast to 2024



Executive Summary

Introduction

Avascular necrosis is the death of the bone tissue due to a lack of blood supply and is also known as osteonecrosis. Avascular necrosis can lead to tiny breaks in the bone, and this eventually leads to the collapsing of bones. This condition is most common in individuals between the ages of 30 and 50. In recent years, the occurrences of avascular necrosis have increased as a result of which the demand for therapeutic surgeries has also increased. This leads to an increase in market growth. The prevalence of avascular necrosis has increased in recent years. The condition also accompanies diseases such as cancer which would have a similar medical condition. According to a study published in the Journal of the Korean Association of Oral and Maxillofacial Surgeons in 2016, the prevalence of bisphosphonate-related necrosis was estimated to be about 2.6% in 2013. The growing cases of bisphosphonate-related necrosis have spurred the growth of the market.

The global avascular necrosis market is expected to reach a market value of USD 1087.1 million by 2024 from USD 699.6 million in 2017 and is expected to register a CAGR of 6.58% during the forecast period from 2018 to 2024. In 2016, the Americas held the highest share of the market at 36.4%, followed by Europe and Asia-Pacific with shares of 26.7% and 24.9%, respectively. The increasing burden of bone disorder in different parts of the world is expected to increase the growth of the market during the forecast period.

The global avascular necrosis market is segmented into type, site, diagnosis, treatment, end-user, and region.

The global avascular necrosis market, by type, is segmented into non-trauma related avascular necrosis and trauma-related avascular necrosis.

The global avascular necrosis market, by site, is segmented into hip bone, knee, shoulders, and others.

The global avascular necrosis market, by diagnosis, is segmented into biopsy and imaging.

The global avascular necrosis market, by treatment, is segmented into electrical stimulation, gene therapy, surgery, and medication.

 

By distribution channel, the global avascular necrosis market is segmented into hospitals and clinics, diagnostic centers, and ambulatory surgical centers.

The global avascular necrosis market is expected to have a value of USD 1087.1 million by 2024 from USD 699.6 million in 2017 and is expected to register a CAGR of 6.58 % during the forecast period from 2018 to 2024.

Key Players

Bayer Healthcare AG, Sanofi, Boehringer Ingelheim GmbH, Pfizer Inc, Merck KGaA, Stryker Corporation, Medtronic PLC, Aurobindo Pharma, Integra Life Sciences Corporation, Zimmer Biomet Holdings, Wright Medical Group N.V., Grifols SA, Smith & Nephew, and Ethicon Inc.

 

Study objectives

To provide a detailed analysis of the market structure along with a forecast of various segments and sub-segments of the global avascular necrosis market

To provide insights into factors influencing and affecting the market growth

To provide historical and forecast revenue of market segments and sub-segments with respect to countries

To provide strategic profiling of key players in the market and comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market

To provide economic factors that influence the global avascular necrosis market

To provide a detailed analysis of the value chain and supply chain of the global avascular necrosis market

Target Audience

Avascular Necrosis Manufacturers

Supplier and Distributors

Pharmaceutical Companies

Research and Development (R&D) Companies

Market Research and Consulting Service Providers

Potential Investors

Raw Material Suppliers

Key Findings

The global avascular necrosis market is expected to reach USD 1087.1 million by 2023 at a CAGR of 6.58 % from 2018 to 2024

On the basis of type, avascular necrosis accounted for the largest market share at a CAGR of 6.20% in 2017

The Americas is expected to hold the largest share of the global avascular necrosis market at a CAGR of 6.32% by 2024.

Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 6.90% by 2024

Regional Analysis

Americas

o North America

? US

? Canada

o South America

Europe

o Germany

o France

o UK

o Italy

o Spain

o Rest of Europe

Asia-Pacific

o Japan

o China

o India

o Australia

o Republic of Korea

o Rest of Asia-Pacific

Middle East & Africa

o Middle East

o Africa

Table of Contents:

 

1 Executive Summary

2 Market Introduction

2.1 Scope of Study

2.2 Research Objective

2.3 List of Assumptions

2.4 Market Structure

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

3.5 Forecast Model

4 Market Dynamics

4.1 Introduction

4.2 Drivers

4.2.1 Increasing awareness along with the high prevalence of the avascular necrosis disease

4.2.2 Rising preference of surgeries to cure osteonecrosis

4.2.3 Rising preference of bone grafting surgical procedures with the less pain substitute procedures

4.2.4 Consolidation of large healthcare providers in the U.S.

4.2.5 Technological advancements in the development of surgical implants

4.3 Restraints

4.3.1 The high cost of surgical procedures and related side effects

4.3.2 Worsening regulatory landscape and growing cost of noncompliance in developed countries

4.4 Opportunities

4.4.1 Growing demand for non-invasive treatments for faster recovery

4.5 Technology Trends & Assessment

4.5.1 Acceptance of synthetic bone-graft over natural ones

4.5.2 Nanotechnology

4.5.3 Rising demand for incorporating recombinant DNA technology in surgical implants

4.5.4 Development of titanium-foam implant for bone grafting

4.5.5 Customized Degradable Implants

5 Market Factor Analysis

5.1 Porter's Five Forces Model

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.2.1 Research & Development

5.2.2 Manufacturing

5.2.3 Distribution

5.2.4 Marketing & Sales

5.2.5 Post-Sales Monitoring

5.3 Epidemiology of Avascular Necrosis

6 Global Avascular Necrosis Market, by Type

6.1 Introduction

6.2 Non-trauma Related Avascular Necrosis

6.2.1 Age Group

6.2.1.1 Third Decade

6.2.1.2 Fifth Decade

6.2.2 Causes

6.2.2.1 Caisson disease

6.2.2.2 Sickle cell anaemia

6.2.2.3 Steroid Abuse

6.2.2.4 Alcohol Abuse

6.3 Trauma-Related Avascular Necrosis

7 Global Avascular Necrosis Market, by Site

7.1 Introduction

7.2 Hip Bone

7.3 Knee

7.4 Shoulder

8 Global Avascular Necrosis Market, by Diagnosis

8.1 Introduction

8.2 Imaging

8.2.1 X-Ray

8.2.2 CT Scan

8.2.3 MRI

8.2.4 PET

8.3 Biopsy

9 Global Avascular Necrosis Market, by Treatment

9.1 Introduction

9.2 Medication

9.2.1 Medication by NSAIDs (Non-Steroidal Anti-inflammatory Drugs)

9.2.2 Medication by Bisphosphonates

9.2.3 Medication by Blood Thinners

9.3 Electrical Stimulation

9.4 Gene Therapy

9.5 Surgery

9.5.1 Core Decompression

9.5.2 Osteotomy

9.5.3 Bone Graft

9.5.4 Arthoplasty

10 Global Avascular Necrosis Market, by End-User

10.1 Introduction

10.2 Hospitals & Clinics

10.3 Diagnostic Centers

10.4 Ambulatory Surgical Centers

11 Global Avascular Necrosis Market, by Region

11.1 Introduction

11.2 Americas

11.2.1 North America

11.2.1.1 U.S.

11.2.1.2 Canada

11.2.2 South America

11.3 Europe

11.3.1 Western Europe

11.3.1.1 Germany

11.3.1.2 France

11.3.1.3 UK

11.3.1.4 Italy

11.3.1.5 Spain

11.3.1.6 Rest of Western Europe

11.3.2 Eastern Europe

11.4 Asia Pacific

11.4.1 Japan

11.4.2 China

11.4.3 India

11.4.4 Australia

11.4.5 Republic of Korea

11.4.6 Rest of Asia Pacific

11.5 The Middle East & Africa

11.5.1.1 The Middle East

11.5.1.2 Africa

12 Competitive Landscape

12.1 Introduction

12.2 Company Market Share Analysis

12.2.1 Introduction

12.3 Key Developments

13 Company Profiles

13.1 Sanofi

13.1.1 Company Overview

13.1.2 Financial Overview

13.1.3 Products Offering

13.1.4 Key Developments

13.1.5 SWOT Analysis

13.1.6 Key Strategy

13.2 Bayer Healthcare AG

13.2.1 Company Overview

13.2.2 Financial Overview

13.2.3 Products Offering

13.2.4 Key Developments

13.2.5 SWOT Analysis

13.2.6 Key Strategy

13.3 Boehringer Ingelheim GmbH

13.3.1 Company Overview

13.3.2 Financial Overview

13.3.3 Products Offering

13.3.4 Key Developments

13.3.5 SWOT Analysis

13.3.6 Key Strategy

13.4 Pfizer Inc.

13.4.1 Company Overview

13.4.2 Financial Overview

13.4.3 Products Offering

13.4.4 Key Developments

13.4.5 SWOT Analysis

13.4.6 Key Strategy

13.5 Merck KGaA

13.5.1 Company Overview

13.5.2 Financial Overview

13.5.3 Products Offering

13.5.4 Key Developments

13.5.5 SWOT Analysis

13.5.6 Key Strategy

13.6 Stryker Corporation

13.6.1 Company Overview

13.6.2 Financial Overview

13.6.3 Products Offering

13.6.4 Key Developments

13.6.5 SWOT Analysis

13.6.6 Key Strategy

13.7 Medtronic PLC

13.7.1 Company Overview

13.7.2 Financial Overview

13.7.3 Products Offering

13.7.4 Key Developments

13.7.5 SWOT Analysis

13.7.6 Key Strategy

13.8 Aurobindo Pharma

13.8.1 Company Overview

13.8.2 Financial Overview

13.8.3 Products Offering

13.8.4 Key Developments

13.8.5 SWOT Analysis

13.8.6 Key Strategy

13.9 Integra LifeSciences Corporation

13.9.1 Company Overview

13.9.2 Financial Overview

13.9.3 Products Offering

13.9.4 Key Developments

13.9.5 SWOT Analysis

13.9.6 Key Strategy

13.1 Zimmer Biomet Holdings

13.10.1 Company Overview

13.10.2 Financial Overview

13.10.3 Products Offering

13.10.4 Key Developments

13.10.5 SWOT Analysis

13.10.6 Key Strategy

13.11 Wright Medical Group N.V.

13.11.1 Company Overview

13.11.2 Financial Overview

13.11.3 Products Offering

13.11.4 Key Developments

13.11.5 SWOT Analysis

13.11.6 Key Strategy

13.12 Grifols SA

13.12.1 Company Overview

13.12.2 Financial Overview

13.12.3 Products Offering

13.12.4 Key Developments

13.12.5 SWOT Analysis

13.12.6 Key Strategy

13.13 Smith & Nephew

13.13.1 Company Overview

13.13.2 Financial Overview

13.13.3 Products Offering

13.13.4 Key Developments

13.13.5 SWOT Analysis

13.13.6 Key Strategy

13.14 Ethicon Inc.

13.14.1 Company Overview

13.14.2 Financial Overview

13.14.3 Products Offering

13.14.4 Key Developments

13.14.5 SWOT Analysis

13.14.6 Key Strategy

14 Conclusion

14.1 Key Findings

14.1.1 CEO's Viewpoint

14.1.2 Unmet Needs

14.1.3 Key Companies to Watch

14.1.4 Prediction

15 Appendix

15.1 Discussion Blue Print

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures:

 

FIGURE 1 GLOBAL AVASCULAR NECROSIS MARKET: MARKET STRUCTURE

FIGURE 2 RESEARCH PROCESS OF MRFR

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH

FIGURE 4 DRO OF GLOBAL AVASCULAR NECROSIS MARKET

FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL AVASCULAR NECROSIS MARKET

FIGURE 6 SUPPLY CHAIN: AVASCULAR NECROSIS MARKET

FIGURE 7 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2010, 2017, 2024 (USD MILLION)

FIGURE 8 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2010, 2017, 2024 (USD MILLION)

FIGURE 9 GLOBAL AVASCULAR NECROSIS MARKET, BY DIAGNOSIS 2010, 2017, 2024 (USD MILLION)

FIGURE 10 GLOBAL AVASCULAR NECROSIS MARKET, BY TREATMENT 2010, 2017, 2024 (USD MILLIONS)

FIGURE 11 GLOBAL AVASCULAR NECROSIS MARKET, BY END-USER 2010, 2017, 2024 (USD MILLION)

FIGURE 12 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2017 & 2024 (USD MILLION)

FIGURE 13 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2017 & 2023 (USD MILLION)

FIGURE 14 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2010, 2017, 2023 (USD MILLION)

FIGURE 15 EUROPE AVASCULAR NECROSIS MARKET, BY COUNTRY, 2010-2024 (USD MILLION)

FIGURE 16 ASIA PACIFIC AVASCULAR NECROSIS MARKET, BY COUNTRY, 2010-2024 (USD MILLION)

FIGURE 17 THE MIDDLE EAST & AFRICA AVASCULAR NECROSIS MARKET, BY COUNTRY, 2010-2024 (USD MILLION)

FIGURE 18 GLOBAL AVASCULAR NECROSIS MARKET, MARKET SHARE ANALYSIS 2017 (%)

FIGURE 19 GLOBAL AVASCULAR NECROSIS MARKET COMPETITIVE LANDSCAPE (%)

List of Tables:

 

TABLE 1 MARKET SYNOPSIS

TABLE 2 LIST OF ASSUMPTIONS

TABLE 3 NORTH AMERICA PROCEDURE NUMBERS, 2010-2016 (UNITS)

TABLE 4 NORTH AMERICA PROCEDURE NUMBERS, 2017-2023 (UNITS)

TABLE 5 SOUTH AMERICA PROCEDURE NUMBERS, 2010-2016 (UNITS)

TABLE 6 SOUTH AMERICA PROCEDURE NUMBERS, 2017-2023 (UNITS)

TABLE 7 EUROPE PROCEDURE NUMBERS, 2010-2016 (UNITS)

TABLE 8 EUROPE PROCEDURE NUMBERS, 2017-2023 (UNITS)

TABLE 9 ASIA PACIFIC PROCEDURE NUMBERS, 2010-2016 (UNITS)

TABLE 10 ASIA PACIFIC PROCEDURE NUMBERS, 2017-2023 (UNITS)

TABLE 11 THE MIDDLE EAST PROCEDURE NUMBERS, 2010-2016 (UNITS)

TABLE 12 THE MIDDLE EAST PROCEDURE NUMBERS, 2017-2023 (UNITS)

TABLE 13 AFRICA PROCEDURE NUMBERS, 2010-2016 (UNITS)

TABLE 14 AFRICA PROCEDURE NUMBERS, 2017-2023 (UNITS)

TABLE 15 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2010-2017 (USD MILLION)

TABLE 16 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2018-2024 (USD MILLION)

TABLE 17 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2010-2017 (PROCEDURE)

TABLE 18 GLOBAL AVASCULAR NECROSIS MARKET, BY TYPE, 2018-2024 (PROCEDURE)

TABLE 19 GLOBAL AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2010-2017 (USD MILLION)

TABLE 20 GLOBAL AVASCULAR NECROSIS MARKET FOR NON-TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2018-2024 (USD MILLION)

TABLE 21 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP, 2010-2017 (USD MILLION)

TABLE 22 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP,2018-2024 (USD MILLION)

TABLE 23 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP, 2010-2017 (PROCEDURE)

TABLE 24 GLOBAL AVASCULAR NECROSIS MARKET, BY AGE GROUP,2018-2024 (PROCEDURE)

TABLE 25 GLOBAL AVASCULAR NECROSIS MARKET FOR THIRD DECADE, BY REGION 2010-2017 (USD MILLION)

TABLE 26 GLOBAL AVASCULAR NECROSIS MARKET FOR THIRD DECADE, BY REGION, 2018-2024 (USD MILLION)

TABLE 27 GLOBAL AVASCULAR NECROSIS MARKET FOR FIFTH DECADE, BY REGION, 2010-2017 (USD MILLION)

TABLE 28 GLOBAL AVASCULAR NECROSIS MARKET FOR FIFTH DECADE, BY REGION, 2018-2024 (USD MILLION)

TABLE 29 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2010-2017 (USD MILLION)

TABLE 30 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2018-2024 (USD MILLION)

TABLE 31 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2010-2017 (PROCEDURE)

TABLE 32 GLOBAL AVASCULAR NECROSIS MARKET, BY CAUSES, 2018-2024 (PROCEDURE)

TABLE 33 GLOBAL AVASCULAR NECROSIS MARKET FOR CAISSON DISEASE, BY REGION, 2010-2017 (USD MILLION)

TABLE 34 GLOBAL AVASCULAR NECROSIS MARKET FOR CAISSON DISEASE, BY REGION, 2018-2024 (USD MILLION)

TABLE 35 GLOBAL AVASCULAR NECROSIS MARKET FOR SICKLE CELL ANAEMIA, BY REGION, 2010-2017 (USD MILLION)

TABLE 36 GLOBAL AVASCULAR NECROSIS MARKET FOR SICKLE CELL ANEMIA, BY REGION, 2018-2024 (USD MILLION)

TABLE 37 GLOBAL AVASCULAR NECROSIS MARKET FOR STEROID ABUSE, BY REGION, 2010-2017 (USD MILLION)

TABLE 38 GLOBAL AVASCULAR NECROSIS MARKET FOR STEROID ABUSE, BY REGION, 2018-2024 (USD MILLION)

TABLE 39 GLOBAL AVASCULAR NECROSIS MARKET FOR ALCOHOL ABUSE, BY REGION, 2010-2017 (USD MILLION)

TABLE 40 GLOBAL AVASCULAR NECROSIS MARKET FOR ALCOHOL ABUSE, BY REGION, 2018-2024 (USD MILLION)

TABLE 41 GLOBAL AVASCULAR NECROSIS MARKET FOR TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2010-2017 (USD MILLION)

TABLE 42 GLOBAL AVASCULAR NECROSIS MARKET FOR TRAUMA RELATED AVASCULAR NECROSIS OR OSTEONECROSIS, BY REGION, 2018-2024 (USD MILLION)

TABLE 43 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2010-2017 (USD MILLION)

TABLE 44 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2018-2024 (USD MILLION)

TABLE 45 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2010-2017 (PROCEDURE)

TABLE 46 GLOBAL AVASCULAR NECROSIS MARKET, BY SITE, 2018-2024 (PROCEDURE)

TABLE 47 GLOBAL AVASCULAR NECROSIS MARKET FOR HIP BONE, BY REGION, 2010-2017 (USD MILLION)

TABLE 48 GLOBAL AVASCULAR NECROSIS MARKET, FOR HIP BONE, BY REGION, 2018-2024 (USD MILLION)

TABLE 49 GLOBAL AVASCULAR NECROSIS MARKET FOR KNEE, BY REGION, 2010-2017 (USD MILLION)

TABLE 50 GLOBAL AVASCULAR NECROSIS MARKET FOR KNEE, BY REGION, 2018-2024 (USD MILLION)

TABLE 51 GLOBAL AVASCULAR NECROSIS MARKET FOR SHOULDER, BY REGION, 2010-2017 (USD MILLION)

TABLE 52 GLOBAL AVASCULAR NECROSIS MARKET FOR SHOULDER, BY REGION, 2018-2024 (USD MILLION)

TABLE 53 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2010-2017 (USD MILLION)

TABLE 54 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2018-2024 (USD MILLION)

TABLE 55 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2010-2017 (PROCEDURE)

TABLE 56 GLOBAL AVASCULAR NECROSIS MARKET BY DIAGNOSIS, 2018-2024 (PROCEDURE)

TABLE 57 GLOBAL AVASCULAR NECROSIS MARKET FOR IMAGING, BY REGION, 2010-2017 (USD MILLION)

TABLE 58 GLOBAL AVASCULAR NECROSIS MARKET FOR IMAGING, BY REGION, 2018-2024 (USD MILLION)

TABLE 59 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2010-2017 (PROCEDURE)

TABLE 60 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2018-2024 (PROCEDURE)

TABLE 61 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2010-2017 (USD MILLION)

TABLE 62 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2018-2024 (USD MILLION)

TABLE 63 GLOBAL AVASCULAR NECROSIS MARKET FOR X-RAY, BY REGION, 2010-2017 (USD MILLION)

TABLE 64 GLOBAL AVASCULAR NECROSIS MARKET FOR X-RAY , BY REGION, 2018-2024 (USD MILLION)

TABLE 65 GLOBAL AVASCULAR NECROSIS MARKET FOR CT SCAN, BY REGION, 2010-2017 (USD MILLION)

TABLE 66 GLOBAL AVASCULAR NECROSIS MARKET FOR CT SCAN, BY REGION, 2018-2024 (USD MILLION)

TABLE 67 GLOBAL AVASCULAR NECROSIS MARKET FOR MRI, BY REGION, 2010-2017 (USD MILLION)

TABLE 68 GLOBAL AVASCULAR NECROSIS MARKET FOR MRI, BY REGION, 2018-2024 (USD MILLION)

TABLE 69 GLOBAL AVASCULAR NECROSIS MARKET FOR PET, BY REGION, 2010-2017 (USD MILLION)

TABLE 70 GLOBAL AVASCULAR NECROSIS MARKET FOR PET, BY REGION, 2018-2024 (USD MILLION)

TABLE 71 GLOBAL AVASCULAR NECROSIS MARKET FOR BIOPSY, BY REGION, 2010-2017 (USD MILLION)

TABLE 72 GLOBAL AVASCULAR NECROSIS MARKET FOR BIOPSY, BY REGION, 2018-2024 (USD MILLION)

TABLE 73 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2010-2017 (USD MILLION)

TABLE 74 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2018-2024 (USD MILLION)

TABLE 75 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2010-2017 (PROCEDURE)

TABLE 76 GLOBAL AVASCULAR NECROSIS MARKET BY TREATMENT, 2018-2024 (PROCEDURE)

TABLE 77 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, BY REGION, 2010-2017 (USD MILLION)

TABLE 78 GLOBAL AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, BY REGION, 2018-2024 (USD MILLION)

TABLE 79 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2010-2017 (USD MILLION)

TABLE 80 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY NSAIDS, 2018-2024 (USD MILLION)

TABLE 81 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2010-2017 (USD MILLION)

TABLE 82 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2018-2024 (USD MILLION)

TABLE 83 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2010-2017 (USD MILLION)

TABLE 84 GLOBAL AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2018-2024 (USD MILLION)

TABLE 85 GLOBAL AVASCULAR NECROSIS MARKET FOR ELECTRICAL STIMULATION, BY REGION, 2010-2017 (USD MILLION)

TABLE 86 GLOBAL AVASCULAR NECROSIS MARKET FOR ELECTRICAL STIMULATION, BY REGION, 2018-2024 (USD MILLION)

TABLE 87 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2010-2017 (USD MILLION)

TABLE 88 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)

TABLE 89 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2010-2017 (USD MILLION)

TABLE 90 GLOBAL AVASCULAR NECROSIS MARKET FOR GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)

TABLE 91 GLOBAL AVASCULAR NECROSIS MARKET FOR SURGERY, BTY TYPE, 2010-2017 (USD MILLION)

TABLE 92 GLOBAL AVASCULAR NECROSIS MARKET FOR SURGERY, BTY TYPE, 2018-2024 (USD MILLION)

TABLE 93 GLOBAL AVASCULAR NECROSIS MARKET FOR SURGERY, BY TYPE, 2010-2017 (PROCEDURE)

TABLE 94 GLOBAL AVASCULAR NECROSIS MARKET FOR SURGERY, BY TYPE, 2018-2024 (PROCEDURE)

TABLE 95 GLOBAL AVASCULAR NECROSIS MARKET FOR CORE DECOMPRESSION, BY REGION, 2010-2017 (USD MILLION)

TABLE 96 GLOBAL AVASCULAR NECROSIS MARKET FOR CORE DECOMPRESSION , BY REGION, 2018-2024 (USD MILLION)

TABLE 97 GLOBAL AVASCULAR NECROSIS MARKET FOR OSTEOTOMY , BY REGION, 2010-2017 (USD MILLION)

TABLE 98 GLOBAL AVASCULAR NECROSIS MARKET FOR OSTEOTOMY, BY REGION, 2018-2024 (USD MILLION)

TABLE 99 GLOBAL AVASCULAR NECROSIS MARKET FOR BONE GRAFT, BY REGION, 2010-2017 (USD MILLION)

TABLE 100 GLOBAL AVASCULAR NECROSIS MARKET FOR BONE GRAFT, BY REGION, 2018-2024 (USD MILLION)

TABLE 101 GLOBAL AVASCULAR NECROSIS MARKET FOR ARTHOPLASTY, BY REGION, 2010-2017 (USD MILLION)

TABLE 102 GLOBAL AVASCULAR NECROSIS MARKET FOR ARTHOPLASTY, BY REGION, 2018-2024 (USD MILLION)

TABLE 103 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2010-2017 (USD MILLION)

TABLE 104 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2018-2024 (USD MILLION)

TABLE 105 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2010-2017 (PROCEDURE)

TABLE 106 GLOBAL AVASCULAR NECROSIS MARKET FOR END USER, BY REGION, 2018-2024 (PROCEDURE)

TABLE 107 GLOBAL AVASCULAR NECROSIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2010-2017 (USD MILLION)

TABLE 108 GLOBAL AVASCULAR NECROSIS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)

TABLE 109 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2010-2017 (USD MILLION)

TABLE 110 GLOBAL AVASCULAR NECROSIS MARKET FOR DIAGNOSTIC CENTERS , BY REGION, 2018-2024 (USD MILLION)

TABLE 111 GLOBAL AVASCULAR NECROSIS MARKET FOR AMBULATORY SURGICAL CENTERS , BY REGION, 2010 2017 (USD MILLION)

TABLE 112 GLOBAL AVASCULAR NECROSIS MARKET FOR AMBULATORY SURGICAL CENTERS , BY REGION, 2018-2024 (USD MILLION)

TABLE 113 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2010-2017 (USD MILLION)

TABLE 114 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2018-2024 (USD MILLION)

TABLE 115 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2010-2017 (PROCEDURE)

TABLE 116 GLOBAL AVASCULAR NECROSIS MARKET, BY REGION, 2018-2024 (PROCEDURE)

TABLE 117 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2010-2017 (USD MILLION)

TABLE 118 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2018-2024 (USD MILLION)

TABLE 119 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2010-2017 (PROCEDURE)

TABLE 120 AMERICAS AVASCULAR NECROSIS MARKET, BY REGION, 2018-2024 (PROCEDURE)

TABLE 121 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2010-2017 (USD MILLION)

TABLE 122 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2018-2024 (USD MILLION)

TABLE 123 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2010-2017 (PROCEDURE)

TABLE 124 AMERICAS AVASCULAR NECROSIS MARKET, BY TYPE, 2018-2024 (PROCEDURE)

TABLE 125 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2010-2017 (USD MILLION)

TABLE 126 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2018-2024 (USD MILLION)

TABLE 127 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2010-2017 (PROCEDURE)

TABLE 128 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2018-2024 (PROCEDURE)

TABLE 129 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2010-2017 (USD MILLION)

TABLE 130 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2018-2024 (USD MILLION)

TABLE 131 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2010-2017 (PROCEDURE)

TABLE 132 AMERICAS NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2018-2024 (PROCEDURE)

TABLE 133 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2010-2017 (USD MILLION)

TABLE 134 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2018-2024 (USD MILLION)

TABLE 135 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2010-2017 (PROCEDURE)

TABLE 136 AMERICAS AVASCULAR NECROSIS MARKET, BY SITE, 2018-2024 (PROCEDURE)

TABLE 137 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2010-2017 (USD MILLION)

TABLE 138 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2018-2024 (USD MILLION)

TABLE 139 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2010-2017 (PROCEDURE)

TABLE 140 AMERICAS AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2018-2024 (PROCEDURE)

TABLE 141 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2010-2017 (USD MILLION)

TABLE 142 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2018-2024 (USD MILLION)

TABLE 143 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2010-2017 (PROCEDURE)

TABLE 144 AMERICAS AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2018-2024 (PROCEDURE)

TABLE 145 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2010-2017 (USD MILLION)

TABLE 146 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2018-2024 (USD MILLION)

TABLE 147 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2010-2017 (PROCEDURE)

TABLE 148 AMERICAS AVASCULAR NECROSIS MARKET, BY TREATMENT, 2018-2024 (PROCEDURE)

TABLE 149 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2010-2017 (USD MILLION)

TABLE 150 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2018-2024 (USD MILLION)

TABLE 151 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2010-2017 (USD MILLION)

TABLE 152 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2018-2024 (USD MILLION)

TABLE 153 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2010-2017 (USD MILLION)

TABLE 154 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2018-2024 (USD MILLION)

TABLE 155 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2010-2017 (USD MILLION)

TABLE 156 AMERICAS AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2018-2024 (USD MILLION)

TABLE 157 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2010-2017 (USD MILLION)

TABLE 158 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2018-2024 (USD MILLION)

TABLE 159 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2010-2017 (PROCEDURE)

TABLE 160 AMERICAS AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2018-2024 (PROCEDURE)

TABLE 161 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2010-2017 (USD MILLION)

TABLE 162 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2018-2024 (USD MILLION)

TABLE 163 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2010-2017 (PROCEDURE)

TABLE 164 AMERICAS AVASCULAR NECROSIS MARKET FOR END USER, 2018-2024 (PROCEDURE)

TABLE 165 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2010-2017 (USD MILLION)

TABLE 166 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2018-2024 (USD MILLION)

TABLE 167 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2010-2017 (PROCEDURE)

TABLE 168 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY REGION, 2018-2024 (PROCEDURE)

TABLE 169 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2010-2017 (USD MILLION)

TABLE 170 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2018-2024 (USD MILLION)

TABLE 171 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2010-2017 (PROCEDURE)

TABLE 172 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TYPE, 2018-2024 (PROCEDURE)

TABLE 173 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2010-2017 (USD MILLION)

TABLE 174 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2018-2024 (USD MILLION)

TABLE 175 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2010-2017 (PROCEDURE)

TABLE 176 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2018-2024 (PROCEDURE)

TABLE 177 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2010-2017 (USD MILLION)

TABLE 178 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2018-2024 (USD MILLION)

TABLE 179 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2010-2017 (PROCEDURE)

TABLE 180 NORTH AMERICA NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2018-2024 (PROCEDURE)

TABLE 181 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2010-2017 (USD MILLION)

TABLE 182 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2018-2024 (USD MILLION)

TABLE 183 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2010-2017 (PROCEDURE)

TABLE 184 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY SITE, 2018-2024 (PROCEDURE)

TABLE 185 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2010-2017 (USD MILLION)

TABLE 186 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2018-2024 (USD MILLION)

TABLE 187 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2010-2017 (PROCEDURE)

TABLE 188 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2018-2024 (PROCEDURE)

TABLE 189 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2010-2017 (USD MILLION)

TABLE 190 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2018-2024 (USD MILLION)

TABLE 191 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2010-2017 (PROCEDURE)

TABLE 192 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2018-2024 (PROCEDURE)

TABLE 193 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2010-2017 (USD MILLION)

TABLE 194 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2018-2024 (USD MILLION)

TABLE 195 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2010-2017 (PROCEDURE)

TABLE 196 NORTH AMERICA AVASCULAR NECROSIS MARKET, BY TREATMENT, 2018-2024 (PROCEDURE)

TABLE 197 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2010-2017 (USD MILLION)

TABLE 198 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2018-2024 (USD MILLION)

TABLE 199 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2010-2017 (USD MILLION)

TABLE 200 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2018-2024 (USD MILLION)

TABLE 201 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2010-2017 (USD MILLION)

TABLE 202 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BISPHOSPHONATES, 2018-2024 (USD MILLION)

TABLE 203 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2010-2017 (USD MILLION)

TABLE 204 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR MEDICATION BY BLOOD THINNERS, 2018-2024 (USD MILLION)

TABLE 205 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2010-2017 (USD MILLION)

TABLE 206 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2018-2024 (USD MILLION)

TABLE 207 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2010-2017 (PROCEDURE)

TABLE 208 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR TREATMENT BY SURGERY, 2018-2024 (PROCEDURE)

TABLE 209 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2010-2017 (USD MILLION)

TABLE 210 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2010-2017 (PROCEDURE)

TABLE 211 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2018-2024 (PROCEDURE)

TABLE 212 NORTH AMERICA AVASCULAR NECROSIS MARKET FOR END USER, 2018-2024 (USD MILLION)

TABLE 213 U.S. AVASCULAR NECROSIS MARKET, BY TYPE, 2010-2017 (USD MILLION)

TABLE 214 U.S. AVASCULAR NECROSIS MARKET, BY TYPE, 2018-2024 (USD MILLION)

TABLE 215 U.S. AVASCULAR NECROSIS MARKET, BY TYPE, 2010-2017 (PROCEDURE)

TABLE 216 U.S. AVASCULAR NECROSIS MARKET, BY TYPE, 2018-2024 (PROCEDURE)

TABLE 217 U.S. NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2010-2017 (USD MILLION)

TABLE 218 U.S. NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2018-2024 (USD MILLION)

TABLE 219 U.S. NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2010-2017 (PROCEDURE)

TABLE 220 U.S. NON-TRAUMA RELATED AVN MARKET, BY AGE GROUP, 2018-2024 (PROCEDURE)

TABLE 221 U.S. NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2010-2017 (USD MILLION)

TABLE 222 U.S. NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2018-2024 (USD MILLION)

TABLE 223 .S. NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2010-2017 (PROCEDURE)

TABLE 224 U.S. NON-TRAUMA RELATED AVN MARKET, BY CAUSES, 2018-2024 (PROCEDURE)

TABLE 225 U.S. AVASCULAR NECROSIS MARKET, BY SITE, 2010-2017 (USD MILLION)

TABLE 226 U.S. AVASCULAR NECROSIS MARKET, BY SITE, 2018-2024 (USD MILLION)

TABLE 227 U.S. AVASCULAR NECROSIS MARKET, BY SITE, 2010-2017 (PROCEDURE)

TABLE 228 U.S. AVASCULAR NECROSIS MARKET, BY SITE, 2018-2024 (PROCEDURE)

TABLE 229 U.S. AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2010-2017 (USD MILLION)

TABLE 230 U.S. AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2018-2024 (USD MILLION)

TABLE 231 U.S. AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2010-2017 (PROCEDURE)

TABLE 232 U.S. AVASCULAR NECROSIS MARKET, BY DIAGNOSIS, 2018-2024 (PROCEDURE)

TABLE 233 U.S. AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2010-2017 (USD MILLION)

TABLE 234 U.S. AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2018-2024 (USD MILLION)

TABLE 235 U.S. AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2010-2017 (PROCEDURE)

TABLE 236 U.S. AVASCULAR NECROSIS MARKET FOR DIAGNOSIS, BY IMAGING, 2018-2024 (PROCEDURE)

TABLE 237 U.S. AVASCULAR NECROSIS MARKET, BY TREATMENT, 2010-2017 (USD MILLION)

TABLE 238 U.S. AVASCULAR NECROSIS MARKET, BY TREATMENT, 2018-2024 (USD MILLION)

TABLE 239 U.S. AVASCULAR NECROSIS MARKET, BY TREATMENT, 2010-2017 (PROCEDURE)

TABLE 240 U.S. AVASCULAR NECROSIS MARKET, BY TREATMENT, 2018-2024 (PROCEDURE)

TABLE 241 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2010-2017 (USD MILLION)

TABLE 242 U.S. AVASCULAR NECROSIS MARKET FOR TREATMENT, BY MEDICATION, 2018-2024 (USD MILLION)

TABLE 243 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2010-2017 (USD MILLION)

TABLE 244 U.S. AVASCULAR NECROSIS MARKET FOR MEDICATION, BY NSAIDS, 2018-2024 (USD MILLIO

Sanofi

Bayer Healthcare AG

Boehringer Ingelheim GmbH

Pfizer Inc

Merck KGaA

Stryker Corporation

Medtronic PLC

Aurobindo Pharma

Integra LifeSciences Corporation

Zimmer Biomet Holdings

Wright Medical Group N.V

Grifols SA

Smith & Nephew

Ethicon Inc


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person